Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols.
Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols.
复制标题
DOI：
10.1186/1477-7827-10-9
复制
发表时间：
2012-02-06
期刊：
影响因子：
--
通讯作者：
Ezcurra D
中科院分区：
文献类型：
--
作者：
Alviggi C;Humaidan P;Ezcurra D
生育力低下患者人群的可变性排除了单一方法控制性卵巢刺激（COS）涵盖患者所有需求的可能性。现代技术导致了新药、治疗方案和定量方法的开发，这些方法可以识别单个患者的特征。这些可能用于匹配患者的正确治疗选择，以优化COS期间的疗效，安全性和耐受性。目前，年龄和促卵泡激素（FSH）水平仍然是临床实践中最常用的单一患者特征。这些变量仅提供成功的基本预后和基于总体患者分类的标准COS治疗的指征。相反，抗苗勒管激素水平似乎是卵巢储备和对COS反应的准确预测因子，并可成功地用于指导COS。窦卵泡计数是一种功能性生物标志物，可用于确定刺激期间所需的FSH剂量和治疗成功率。最后，在未来，遗传筛查可能允许基于基因型预测COS期间个体患者对刺激的反应。不幸的是，尽管这些措施的预测能力，没有一个单一的生物标志物可以单独作为指导，以确定最佳的治疗方案。在未来，激素，功能和遗传生物标志物将一起用于个性化COS。
Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify single patient characteristics. These could potentially be used to match patients with the right treatment options to optimise efficacy, safety and tolerability during COS. Currently, age and follicle-stimulating hormone (FSH) level remain the most commonly used single patient characteristics in clinical practice. These variables only provide a basic prognosis for success and indications for standard COS treatment based on gross patient categorisation. In contrast, the anti-Müllerian hormone level appears to be an accurate predictor of ovarian reserve and response to COS, and could be used successfully to guide COS. The antral follicle count is a functional biomarker that could be useful in determining the dose of FSH necessary during stimulation and the success of treatment. Finally, in the future, genetic screening may allow an individual patient's response to stimulation during COS to be predicted based on genotype. Unfortunately, despite the predictive power of these measures, no single biomarker can stand alone as a guide to determine the best treatment option. In the future, hormonal, functional and genetic biomarkers will be used together to personalise COS.
登录
查看更多内容
影响因子：
6.7
作者：
Detti, L;Williams, DB;Thomas, MA
通讯作者：
Thomas, MA
影响因子：
6.7
作者：
Ferraretti, AP;Gianaroli, L;Montanaro, N
通讯作者：
Montanaro, N
影响因子：
2.6
作者：
Behre, HM;Greb, RR;Simoni, M
通讯作者：
Simoni, M
影响因子：
5
作者：
Freour, Thomas;Mirallie, Sophie;Masson, Damien
通讯作者：
Masson, Damien
DOI：
10.1111/j.0001-6349.2005.00736.x
发表时间：
2005-08-01
影响因子：
4.3
作者：
Falconer, H;Andersson, E;Fried, G
通讯作者：
Fried, G